{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Neoplasm+in+the+Stomach&page=8",
    "query": {
      "condition": "Metastatic Malignant Neoplasm in the Stomach",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 185,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Neoplasm+in+the+Stomach&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Neoplasm+in+the+Stomach&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T21:54:50.432Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01641939",
      "title": "A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Taxane",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab emtansine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 415,
      "start_date": "2012-09-03",
      "completion_date": "2016-04-30",
      "has_results": true,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 10,
      "location_summary": "Bakersfield, California • Stanford, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01641939"
    },
    {
      "nct_id": "NCT00010283",
      "title": "Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Gestational Trophoblastic Tumor",
        "Graft Versus Host Disease",
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "beclomethasone dipropionate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "5 Years to 75 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-07",
      "completion_date": "2002-07",
      "has_results": false,
      "last_update_posted_date": "2010-04-02",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00010283"
    },
    {
      "nct_id": "NCT07807345",
      "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head & Neck Squamous Cell Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Colorectal Cancer",
        "Endometrial Cancer",
        "Urothelial Carcinoma (UC)",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "STRO-006",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 285,
      "start_date": "2026-09-14",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Orlando, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Irving",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07807345"
    },
    {
      "nct_id": "NCT01643499",
      "title": "Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acinar Cell Adenocarcinoma of the Pancreas",
        "Adenocarcinoma of the Gallbladder",
        "Adenocarcinoma of Unknown Primary",
        "Adult Primary Cholangiocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Cholangiocarcinoma of the Extrahepatic Bile Duct",
        "Cholangiocarcinoma of the Gallbladder",
        "Diffuse Adenocarcinoma of the Stomach",
        "Duct Cell Adenocarcinoma of the Pancreas",
        "Intestinal Adenocarcinoma of the Stomach",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Metastatic Carcinoma of Unknown Primary",
        "Metastatic Extrahepatic Bile Duct Cancer",
        "Mixed Adenocarcinoma of the Stomach",
        "Mucinous Adenocarcinoma of the Colon",
        "Mucinous Adenocarcinoma of the Rectum",
        "Newly Diagnosed Carcinoma of Unknown Primary",
        "Signet Ring Adenocarcinoma of the Colon",
        "Signet Ring Adenocarcinoma of the Rectum",
        "Stage III Pancreatic Cancer",
        "Stage IIIA Colon Cancer",
        "Stage IIIA Gallbladder Cancer",
        "Stage IIIA Gastric Cancer",
        "Stage IIIA Rectal Cancer",
        "Stage IIIB Colon Cancer",
        "Stage IIIB Gallbladder Cancer",
        "Stage IIIB Gastric Cancer",
        "Stage IIIB Rectal Cancer",
        "Stage IIIC Colon Cancer",
        "Stage IIIC Gastric Cancer",
        "Stage IIIC Rectal Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IVA Colon Cancer",
        "Stage IVA Gallbladder Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Gallbladder Cancer",
        "Stage IVB Rectal Cancer",
        "Unresectable Extrahepatic Bile Duct Cancer"
      ],
      "interventions": [
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2012-03-26",
      "completion_date": "2019-07",
      "has_results": false,
      "last_update_posted_date": "2020-05-08",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Evanston, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01643499"
    },
    {
      "nct_id": "NCT01774851",
      "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER-2 Gene Amplification",
        "Esophagus Cancer",
        "Gastroesophageal Junction Cancer",
        "Stomach Cancer"
      ],
      "interventions": [
        {
          "name": "MM-111",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merrimack Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2013-01",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-06-22",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01774851"
    },
    {
      "nct_id": "NCT03071757",
      "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-368",
          "type": "DRUG"
        },
        {
          "name": "ABBV-181",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2017-03-21",
      "completion_date": "2022-04-13",
      "has_results": false,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Sacramento, California • Stanford, California + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03071757"
    },
    {
      "nct_id": "NCT05523947",
      "title": "Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-Positive Solid Tumor"
      ],
      "interventions": [
        {
          "name": "YH32367",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yuhan Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2022-08-26",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05523947"
    },
    {
      "nct_id": "NCT06295094",
      "title": "The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer",
        "Chemotherapy, Adjuvant",
        "Peritoneal Metastases",
        "Minimally Invasive Surgical Procedures"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Odense University Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 264,
      "start_date": "2024-09",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-06",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06295094"
    },
    {
      "nct_id": "NCT03849469",
      "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Triple Negative Breast Cancer",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Carcinoma",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced or Metastatic Solid Tumors",
        "Prostate Carcinoma",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Squamous Cell Anal Cancer",
        "Squamous Cell Penile Carcinoma",
        "Squamous Cell Vulvar Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "XmAb®22841",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (Keytruda®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-05-29",
      "completion_date": "2023-02-16",
      "has_results": false,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 28,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03849469"
    },
    {
      "nct_id": "NCT00253370",
      "title": "Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Metastatic Gastric Cancer",
        "Advanced Unresectable Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "BAY 43-9006",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2005-10",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-11-24",
      "last_synced_at": "2026-10-14T21:54:50.432Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00253370"
    }
  ]
}